Rabara et al. [150] confirmed these results and further showed that a subset of KRASG13D-mutated colorectal adenocarcinomas had co-mutation of NF1. Only KRASG13D-mutated cancers with WT NF1 were responsive to EGFR inhibition. This evidence concerns the gene EGFR and colorectal adenocarcinoma.